N4 Pharma Plc (N4P.L)
- Previous Close
0.5500 - Open
0.6000 - Bid --
- Ask --
- Day's Range
0.5000 - 0.6000 - 52 Week Range
0.5000 - 2.1000 - Volume
634,134 - Avg. Volume
730,878 - Market Cap (intraday)
1.613M - Beta (5Y Monthly) -0.19
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Sep 10, 2024 - Sep 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date May 19, 1997
- 1y Target Est
--
N4 Pharma Plc, a specialist pharmaceutical company, develops silica nanoparticle delivery systems to enhance the cellular delivery of cancer treatments, gene therapy, and vaccines in the United Kingdom. It develops Nuvec, which offers silica nanoparticles with irregular surface structure and polyethyleneimine that traps and protects nucleic acid; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene for the treatment of glaucoma. The company was incorporated in 1979 and is based in London, the United Kingdom.
www.n4pharma.com5
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: N4P.L
Performance Overview: N4P.L
Trailing total returns as of 6/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: N4P.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: N4P.L
Valuation Measures
Market Cap
1.48M
Enterprise Value
451.18k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
684.02
Price/Book (mrq)
1.31
Enterprise Value/Revenue
231.02
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-51.74%
Return on Equity (ttm)
-77.81%
Revenue (ttm)
1.95k
Net Income Avi to Common (ttm)
-1.27M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
1.03M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-823.63k